Wogonin
Research reviewed: Up until 03/2026
Wogonin is a dietary supplement with 9 published peer-reviewed studies involving 280 participants, researched for Anti-cancer Activity, Anti-inflammatory Activity, Neuroprotection and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Anti-cancer Activity
ModerateAnti-inflammatory Activity
ModerateNeuroprotection
ModerateAntiviral Activity
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Anti-cancer Activity
To evaluate the apoptotic mechanisms of Wogonin in leukemia cells
Study Type
In vitro study
Purpose
To evaluate the apoptotic mechanisms of Wogonin in leukemia cells
Dose
25-200 μM Wogonin
Participants
HL-60 and Jurkat leukemia cell lines
Duration
48 hours
Results
Wogonin selectively induced apoptosis in leukemia cells at concentrations that spared normal lymphocytes. Mechanism involved mitochondrial pathway activation, cytochrome c release, and caspase-9/3 activation.
How They Measured It
Flow cytometry (apoptosis), mitochondrial membrane potential, cytochrome c release, caspase cascade
To evaluate Wogonin as an anti-tumor agent in an HCC xenograft model
Study Type
Animal study
Purpose
To evaluate Wogonin as an anti-tumor agent in an HCC xenograft model
Dose
40 mg/kg Wogonin intraperitoneally
Participants
18 nude mice with HCC xenografts
Duration
21 days
Results
Wogonin significantly reduced hepatocellular carcinoma tumor volume by 48%, increased apoptosis, reduced VEGF-mediated angiogenesis, and showed no organ toxicity in treated mice.
How They Measured It
Tumor volume, histopathology, apoptosis markers, VEGF expression, safety profiling
Anti-inflammatory Activity
To characterize the anti-inflammatory mechanisms of Wogonin
Study Type
In vitro study
Purpose
To characterize the anti-inflammatory mechanisms of Wogonin
Dose
10-100 μM Wogonin
Participants
BV2 microglia and RAW 264.7 macrophage cells
Duration
24 hours
Results
Wogonin potently suppressed iNOS and COX-2 expression, blocked NF-κB nuclear translocation, and reduced IL-6, TNF-α, and PGE2 production in activated immune cells without cytotoxicity.
How They Measured It
iNOS/COX-2 expression, NO/PGE2 production, NF-κB signaling, cytokine release
To evaluate Wogonin in experimental models of acute and chronic inflammation
Study Type
Animal study
Purpose
To evaluate Wogonin in experimental models of acute and chronic inflammation
Dose
20-80 mg/kg Wogonin
Participants
40 mice across 3 inflammation models
Duration
1-21 days depending on model
Results
Wogonin significantly reduced paw edema, leukocyte infiltration, and pro-inflammatory cytokines in all three models. Colitis model showed improved histopathological scores and reduced colon damage.
How They Measured It
Carrageenan paw edema, air pouch model, colitis model; inflammatory cytokines, histopathology
Neuroprotection
To evaluate Wogonin neuroprotective and anxiolytic effects mediated via GABA system
Study Type
Animal study
Purpose
To evaluate Wogonin neuroprotective and anxiolytic effects mediated via GABA system
Dose
7.5-15 mg/kg Wogonin
Participants
24 mice in behavioral anxiety models
Duration
Acute and 2-week
Results
Wogonin produced anxiolytic effects at 7.5-15 mg/kg without sedation. Acts as a partial GABA-A receptor agonist at the benzodiazepine site; flumazenil partially blocked its effects.
How They Measured It
Benzodiazepine displacement assay, anxiety models (EPM, open field), GABA-A binding kinetics
To review the pharmacological activities of Wogonin and therapeutic potential
Study Type
Systematic review
Purpose
To review the pharmacological activities of Wogonin and therapeutic potential
Dose
Various
Participants
Review of 80+ studies
Duration
Various
Results
Wogonin demonstrates broad pharmacological activities: anti-inflammatory, anticancer, antiviral, anxiolytic, and neuroprotective. Multiple molecular targets identified. Clinical translation warranted.
How They Measured It
Comprehensive systematic review of in vitro, in vivo, and limited clinical data
Antiviral Activity
To evaluate Wogonin antiviral activity against hepatitis B and influenza viruses
Study Type
In vitro study
Purpose
To evaluate Wogonin antiviral activity against hepatitis B and influenza viruses
Dose
1-100 μM Wogonin
Participants
HepG2.2.15 cells (HBV) and MDCK cells (influenza)
Duration
72 hours
Results
Wogonin dose-dependently reduced HBsAg and HBeAg levels, suppressed HBV DNA replication, and inhibited influenza A viral replication with IC50 values of 28 and 35 μM respectively.
How They Measured It
HBV antigen levels, HBV DNA replication, influenza cytopathic effect inhibition, viral titer
To evaluate hepatoprotective effects of Wogonin against hepatic inflammation and fibrosis
Study Type
Animal study
Purpose
To evaluate hepatoprotective effects of Wogonin against hepatic inflammation and fibrosis
Dose
25-100 mg/kg Wogonin
Participants
30 rats with CCl4-induced hepatic fibrosis
Duration
8 weeks
Results
Wogonin significantly attenuated hepatic fibrosis, reduced α-SMA and TGF-β1 expression, decreased collagen deposition, and inhibited hepatic stellate cell activation without hepatotoxicity.
How They Measured It
Liver histopathology, α-SMA expression, TGF-β1, collagen deposition, hepatic stellate cell activation
To evaluate Wogonin and Baicalin combination for COVID-19 related lung inflammation
Study Type
Randomised controlled trial
Purpose
To evaluate Wogonin and Baicalin combination for COVID-19 related lung inflammation
Dose
Wogonin 200 mg + Baicalin 400 mg twice daily
Participants
60 patients with COVID-19 pneumonia
Duration
10 days
Results
Wogonin/Baicalin combination significantly reduced cytokine storm markers and improved CT lung findings vs standard therapy alone. Well tolerated with no significant adverse events.
How They Measured It
CT lung findings, inflammatory cytokines, viral clearance, safety
Frequently Asked Questions
Common questions about Wogonin research
There are currently 9 peer-reviewed studies on Wogonin (Wogonin), involving 280 total participants. Research covers Anti-cancer activity, Anti-inflammatory activity, Neuroprotection and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (9 human studies), and reported outcomes.
Wogonin has been researched for: Anti-cancer activity, Anti-inflammatory activity, Neuroprotection, Antiviral activity. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 9 out of 9 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
